[go: up one dir, main page]

WO2025104432A1 - Composition comprenant de la terbinafine et un polymère destinée à être utilisée dans le traitement de l'onychomycose - Google Patents

Composition comprenant de la terbinafine et un polymère destinée à être utilisée dans le traitement de l'onychomycose Download PDF

Info

Publication number
WO2025104432A1
WO2025104432A1 PCT/GB2024/052885 GB2024052885W WO2025104432A1 WO 2025104432 A1 WO2025104432 A1 WO 2025104432A1 GB 2024052885 W GB2024052885 W GB 2024052885W WO 2025104432 A1 WO2025104432 A1 WO 2025104432A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
terbinafine
foot
hand
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/GB2024/052885
Other languages
English (en)
Inventor
Juergen DOBMEYER
Kerry Nield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanoderm Ltd
Original Assignee
Sanoderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2317378.4A external-priority patent/GB202317378D0/en
Priority claimed from GBGB2318443.5A external-priority patent/GB202318443D0/en
Application filed by Sanoderm Ltd filed Critical Sanoderm Ltd
Publication of WO2025104432A1 publication Critical patent/WO2025104432A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • compositions comprising nanoparticles formed of a polymer and terbinafine.
  • Such compositions are particularly suited, but not limited, to the treatment of fungal nail and/or skin infections.
  • the major classes of antifungals currently used are polyenes, azoles allyl amines, lipopeptides, and pyrimidines. However, polyenes are toxic to mammalian cells. Azoles are well tolerated topically but have side effects when given systemically and there have been several reports of resistance to azoles. Flucytosine is the most common pyrimidine used. Whilst it has excellent tissue penetration, resistance against flucytosine can develop rapidly and produce gastro intestinal side effects. Lipopetides display low toxicity and several trials are still on going to test efficacy.
  • Onychomycosis (more commonly known as fungal nail infection) causes nails to thicken, discolor, disfigure, and split. Without treatment, the nails can become so thick that they press against the inside of shoes, causing pressure, irritation, and pain. There are risks for further complications especially in patients with diabetes, those with peripheral vascular disease and the immunocompromised patient.
  • Fungal nail infection may cause psychological and social problems. The incidence of fungal nail infection increases with age and has a prevalence of -30% of the over 60s with significant incidence in Europe with even higher levels in Asia. Fungal nail infection may affect one or more toenails and/or fingernails and can completely destroy the nail if left untreated.
  • the current treatment for fungal nail infection is as topical nail lacquer/paint (such as amorolfine) 1-2 times per week for 6-12 months and/or oral antifungals (such as terbinafine or itraconazole).
  • Oral antifungals can have severe side effects such as gastro-intestinal upset and can even result in liver failure. Relapse is commonly reported and many patients will not commit to the treatment course due to predicted side effects and length of treatment time and often only when disease becomes more aggressive will treatment begin.
  • Current oral or topical treatments can take 6-12 months to work. Oral treatments have to saturate the systemic circulation to reach the toes and the increased doses increases the risk to the gastro-intestinal and liver complications.
  • WO2019/002862 discloses a composition for use in the treatment of onychomycosis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5pg to about 50pg of terbinafine.
  • An object of the present invention is to address one or more of the above problems associated with current anti-fungal treatments.
  • One object of the present invention is to provide a topical anti-fungal treatment.
  • Another object of the present invention is to provide a treatment which allows for better penetration of an anti-fungal agent through the nail and/or dermis.
  • a further objective is to provide an effective dose of active ingredient in a topical anti-fungal treatment to treat onychomycosis. It is desirable if the present invention could be used as a treatment for addressing onychomycosis and also be easily applied resulting in a high treatment adherence and have a low re-occurrence rate.
  • compositions for use in the treatment of onychomycosis in a foot and/or hand of an individual comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an affected area of each foot and/or hand and/or digit and/or the inter-digital spaces in the range of about 100pg to about 1mg of terbinafine.
  • a composition for use as a medicament for use in the treatment of onychomycosis in a foot and/or hand of an individual, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand in the range of about 100pg to about 1 mg of terbinafine.
  • a composition for the treatment of onychomycosis in a foot and/or hand of an individual comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an affected area of the digits and/or the interdigital spaces and/or each foot and/or hand in the range of about 100pg to about 1 mg of terbinafine.
  • compositions for the manufacture of a medicament for the treatment of onychomycosis in a foot and/or hand of an individual comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand in the range of about 100pg to about 1 mg of terbinafine.
  • a method of treating onychomycosis in a foot and/or hand of a patient by topically administering to a patient in need thereof, a composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered in a daily dose to an affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand in the range of about 100pg to about 1mg of terbinafine.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 50 pg to 1 mg.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 75 pg to about 1 mg.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 300pg to about 1mg.
  • the daily dose to an affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is about 1 mg.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 50 pg to about 300 pg.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 75 pg to about 300 pg.
  • the daily dose to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand of terbinafine is in the range of about 100 pg to about 300 pg.
  • the term “daily dose” is intended to mean the quantity of terbinafine which is topically applied to an affected area of the digits and/or the inter-digital spaces and/or foot and/or hand, of an individual or animal suffering from onychomycosis. It is envisaged that more than one area of the individual or animal may be affected with onychomycosis and therefore require separate doses of the composition. Typically, both feet and/or hands will be treated at the same time. When both feet and/or hands are treated at the same time the daily dose is intended to be the daily dose applied to each foot or hand.
  • the daily dose will preferably consist of a topical application twice daily (such as once in the morning and once in the evening).
  • the daily dose may comprise up to about 10 spray applications (i.e. about 5 spray applications in the morning and about 5 spray applications in the evening).
  • compositions for use in the treatment of onychomycosis in a foot and/or hand of an individual comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof, and wherein the composition is administered topically by means of a spray application using one or more spray applications to provide a daily spray dose of up to about 1 mg of terbinafine to the affected area of the digits and/or the inter-digital spaces and/or each foot and/or hand.
  • the daily spray dose comprises up to about 10 spray applications, with up to about 5 spray applications administered twice a day. It is preferred that both feet and/or hands are treated at the same time.
  • the spray will preferably be effective to cover the digits and/or the inter-digital spaces and/or the foot and/or hand.
  • Each spray application may dispense up to about 100 mg of liquid.
  • the composition may be atomised during each spray application.
  • the spray application may be administered by means of a pump-action spray device or a metered aerosol spray device.
  • the pump-action spray device may be a metered pump-action spray device.
  • the metered pump-action or metered aerosol spray device may be set to dispense 100 pL of liquid in each pump or spray of the device. Both the pump-action and aerosol spray devices are those that dispense the correct metered volume of liquid whether the device is used upright or in any other orientation including upside down.
  • metered pump-action and metered aerosol spray devices suitable for use with the composition of the invention and that are available to the skilled person.
  • the daily dose may be for administration for up to about 48 weeks, up to about 36 weeks, up to about 12 weeks, or up to about 4 weeks.
  • a combination of a composition for use in the treatment of onychomycosis in a foot and/or hand of an individual and a composition dispensing device for dispensing a pre-defined quantity of composition to the digits and/or the inter-digital spaces and/or foot and/or hand of an individual comprising a vessel containing the composition, an atomising nozzle, and an actuation arrangement operable by the user to dispense the predefined quantity of composition from the vessel via the nozzle, thereby atomizing the composition
  • the composition comprises a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof, and wherein the pre-defined quantity of the composition contains terbinafine in the range of about 1Opg to about 100pg per actuation of the dispensing device.
  • the pre-defined quantity of the composition may comprise about 10OpI of liquid.
  • the actuation arrangement may be a pump-action spray device or a metered aerosol spray device.
  • the spray should be effective to cover the entire affected area, digits and/or the interdigital spaces and/or front of the foot and/or hand so as to be able to treat onychomycosis and surrounding area.
  • the composition as herein above described, and the composition of the combination may comprise: a) terbinafine, or derivative or salt thereof, tin an amount in the range of 0.01 % w/v to about 0.1 % w/v; and b) a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the polymer is present in an amount of about 0.03% w/v to about 0.3%
  • the composition may further comprise up to about 30% (w/v) alcohol.
  • the composition may further comprise alcohol at between about 20% (w/v) and about 30% (w/v).
  • the composition may further comprise alcohol at up to about 20% (w/v).
  • the alcohol is present in the composition at about 20% (w/v).
  • the polymer may comprise one or more of polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB) or polyethylene hexamethylene biguanide (PEHMB).
  • PHMB polyhexamethylene biguanide
  • PHMG polyhexamethylene monoguanide
  • PEB polyethylene biguanide
  • PTMB polytetramethylene biguanide
  • PEHMB polyethylene hexamethylene biguanide
  • the polymer may comprise homogeneous or heterogeneous mixtures of one or more of polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB), polyethylene hexamethylene biguanide (PEHMB), polymethylene biguanides (PMB), poly(allylbiguanidnio- co-allylamine), poly(N-vinylbiguanide), polyallybiguanide.
  • PHMB polyhexamethylene biguanide
  • PHMG polyhexamethylene monoguanide
  • PEB polyethylene biguanide
  • PTMB polytetramethylene biguanide
  • PEHMB polymethylene biguanides
  • PMB poly(allylbiguanidnio- co-allylamine
  • poly(N-vinylbiguanide) polyallybiguanide.
  • the most preferred polymer comprises polyhexamethylene biguanide (PHMB).
  • terbinafine, or derivative or salt thereof is intended to mean the pharmaceutically active substance related to terbinafine hydrochloride, which is a synthetic allylamine antifungal originally marketed under the trade name Lamisil®.
  • Lamisil® a synthetic allylamine antifungal originally marketed under the trade name Lamisil®.
  • the term is also intended to include pharmaceutical variations, derivatives, alternative salts, of terbinafine hydrochloride such as non-toxic organic, or inorganic, acid, or base, addition salt, in a pharmaceutically acceptable form.
  • the alcohol will preferably comprise ethanol, although it may comprise (whether alone or in combination with) other alcohols such as methanol or propanol.
  • the composition may also comprise water.
  • the water will preferably be purified, for example the water may be distilled water.
  • the water may be present in an amount in a formulation in the range of about 70% to about 95% (v/v).
  • the water will be in a formulation in an amount in the range of about 70% to about 90% (v/v).
  • the water will be in a formulation in an amount in the range of about 70% to about 80% (v/v).
  • the water will be in a formulation in an amount over about 77% (v/v).
  • the water is in a formulation in an amount up to about 90% (v/v), up to about 80% (v/v) or up to about 79.6% (v/v).
  • the water may be present in an amount in a formulation in the range of about 70% to about 95% (w/v).
  • the water will be in a formulation in an amount in the range of about 70% to about 90% (w/v). More preferably, the water will be in a formulation in an amount in the range of about 70% to about 80% (w/v). Yet more preferably, the water will be in a formulation in an amount over about 77% (w/v). Most preferably, the water is in a formulation in an amount up to about 90% (w/v), up to about 80% (w/v) or up to about 79.6% (w/v).
  • composition may further comprise one or more of the following components: buffers, excipients, binders, oils, solvents, water, emulsifiers, glycerin, antioxidants, preservatives and fragrances or any additional components usually found in medicaments.
  • a number of techniques may be employed to further process the mixture so as to select the nanoparticles in the required size ranges, such as centrifugation, electrophoretic, chromatographic or filtration methods.
  • the measurement of the size/diameter of the nanoparticles is preferably conducted using dynamic light scattering analysis.
  • the composition dispensing device may further comprise a metering valve, through which the pre-defined quantity of composition is dispensed. It is preferred that the pre-defined quantity of composition comprises up to about 100 pl.
  • composition dispensing device may further comprise and/or be associated with a distance indicator or measurement device to indicate the correct distance the user should place the nozzle of the device relative to the infected area (such as their digits and/or inter-digital spaces and/or front of the foot or hand or limb).
  • a distance indicator or measurement device to indicate the correct distance the user should place the nozzle of the device relative to the infected area (such as their digits and/or inter-digital spaces and/or front of the foot or hand or limb).
  • composition according to the invention may be formulated into a number of different formulations with differing concentrations of each component.
  • Example formulations are included below:
  • Example formulation D Example formulation E:
  • Figure 1 is a bar graph showing the data from a clinical trial in which the nails of patients with confirmed fungal nail infections were sprayed daily for 12 weeks with compositions comprising either BB2603 (terbinafine and PHMB nanoparticles, i.e. nanoparticles that comprise both terbinafine and PHMB and are a complex of terbinafine and PHMB) or with a negative control (PHMB without terbinafine) (Vehicle).
  • Patients treated with BB2603 were given one of three different compositions containing different concentrations of terbinafine.
  • Figure 2 is a swim lane analysis table showing the results of a clinical trial in which the nails of patients with confirmed fungal nail infections were sprayed daily for 12 weeks with compositions comprising either BB2603-10 (terbinafine and PHMB nanoparticles providing a daily dose of 1 mg terbinafine) or with a negative control (PHMB without terbinafine) (Vehicle).
  • Each box of the table represents the recorded mycological effects of treatment on an individual patient at a given time point.
  • Each row of each table represents a different patient.
  • Each column of each table represents a different time point before or after treatment, with the second column being the end of treatment and the far-right column representing 9 months after treatment.
  • Figure 3 is a line graph showing the results of a clinical trial in which the nails of patients with confirmed fungal nail infections were sprayed daily for 12 weeks with compositions comprising BB2603-10 (terbinafine and PHMB nanoparticles) to provide a daily dose to each foot of 1 mg terbinafine.
  • the results show that over 85% of patients exhibited fungal negative cultures immediately after treatment (12 weeks) which decreased to about 64% after 52 weeks.
  • the results also show a 20-30% increase in the percentage of patients that were confirmed as KOH negative from 12 to 52 weeks, and a 15-20% increase in the percentage of patients that were confirmed as mycologically cured in the same period.
  • Figure 4 is a line graph showing the results of a clinical trial in which the nails of patients with confirmed fungal nail infections were sprayed daily for 12 weeks with compositions comprising PHMB without terbinafine (vehicle). The results show no significant difference between the percentage of patients that exhibited fungal negative cultures immediately after treatment (12 weeks) or at any point up to week 52. Additionally, there was no significant difference between the percentage of patients that were confirmed as KOH negative or mycologically cured immediately after treatment, or at any point up to 52 weeks.
  • compositions comprising nanoparticles of PHMB and terbinafine in amounts of up to 1 mg/day of terbinafine per foot.
  • the study was carried out as a randomised, double-blinded trial comprising a four-arm parallel assignment intervention model. Each group was topically administered twice daily with one of the following compositions: Vehicle, BB2603-1. BB2603-3 and BB2603-10. All four compositions comprised a polyhexanide/ 20% ethanol/ water formulation. BB2603-1 , BB2603- 3 and BB2603-10 further comprised 0.01% w/v, 0.03% w/v, and 0.1 % w/v of terbinafine respectively.
  • composition had 300 pg, 90 pg or 30 pg polyhexanide respectively per pump actuation (0.3% w/v, 0.09% w/v, 0.03% w/v).
  • compositions were administered twice daily, once in the morning, once in the evening, as a 5-pump dose on each foot.
  • Each treatment provided either 0.3 mg, 0.09 mg, or 0.03 mg respectively of polyhexanide per day.
  • compositions comprising the Vehicle negative control
  • Vehicle negative control comprise a polyhexanide/ 20% ethanol/ water formulation.
  • Participants were male or female, recruited in Germany, Poland or the Czech Republic, aged 18-99 years (>95% of participants 75 years or younger) with confirmed onychomycosis (fungal nail infection) affecting >25% to ⁇ 60% of the target toenail as determined through clinimetric measurement.
  • the age distribution of participants was representative of the expected population with onychomycosis in those countries.
  • Participants were excluded from entering the trial if they had previously had topical treatment with antifungal medication within 12 weeks before the beginning of trial treatment, had systemic use of an anti-fungal treatment within 12 months before the start of trial treatment, or had past use of laser therapy, photodynamic therapy, chemical, surgical, or relevant mechanical removal for OM within 6 months of the start of trial treatment.
  • Table 1 shows the percentage area of each nail infected with OM.
  • Table 2 shows the profile of dermatophyte species detected in target toenails prior to the beginning of treatment. The percentage of affected nail prior to treatment was balanced across all groups. Additionally, it was determined that the most prevalent dermatophyte species was T rubrum, with over 70% of subjects being infected.
  • Table 1 Percentage Disease in Target Toenail at the start of treatment for each of the 4 treatment groups (eligibility for inclusion into the study, ⁇ 25- ⁇ 60% was established at V1 screening).
  • compositions were provided to participants in 30 mL plastic bottles comprising a handpump spray attachment. Each participant was given instructions to self-administer treatment by spraying five pumps of the provided composition on to each foot; once in the morning, once in the evening, for a period 12 weeks. Participants were asked to record the time of each topical application and to provide reasons for any missed or incorrect applications.
  • Treatment effects were determined during regular participant visits. Participants were asked to visit the trial sites at weeks 12, 16, 28, 40 and 52. During visits after the treatment period, samples were taken of the infected area and used to determine the mycological effects of each treatment. Clinimetric data, such as clear nail growth and percentage of nail area infected measured by a grid were also determined, in addition to any relevant safety and tolerability data including any adverse effects.
  • Table 3 Status of participants. There were no withdrawals due to adverse effects. Notably, a higher proportion of participants from the Vehicle group withdrew from the study when compared to the proportion of those in the BB2603-10 group.
  • mITT+LOCF modified Intention to Treat with Last observation carried forward
  • Per Protocol Analysis modified Intention to Treat without Last observation carried forward
  • mITT no LOCF modified Intention to Treat without Last observation carried forward
  • the study met the primary endpoints; statistically significantly more participants in the BB2603-10 group had negative dermatophyte culture and/or clear nail growth at Week 16 (early response assessment) compared to vehicle-treated participants (83.3% vs 51.4%, p 0.004).
  • BB2603-10 is an excellent candidate for the effective treatment of OM.
  • Figure 3 also shows that there was a significant increase from Week 12 to Week 52 in the percentage of negative KOH microscopy tests and the percentage of participants that were mycologically cured from Week 12 to Week 52. These results are consistent with nails that grow out clear of infection.
  • Figure 4 shows that there was no difference in the percentage of culture negative, KOH microscopy negative or mycologically cured participants over the study duration when treated with the Vehicle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition destinée à être utilisée dans le traitement de l'onychomycose du pied et/ou de la main d'un individu, la composition comprenant un polymère pouvant former des nanoparticules et de la terbinafine, ou un dérivé ou un sel associé, les nanoparticules étant formées avec et/ou en présence de terbinafine, ou d'un dérivé ou d'un sel associé et la composition étant administrée par voie topique pour fournir une dose quotidienne à une zone affectée des doigts et/ou des espaces interdigitaux et/ou de chaque pied et/ou main dans la plage d'environ 100 µg à environ 1 mg de terbinafine. L'invention porte également sur une combinaison de la composition et d'un dispositif de distribution de liquide pour distribuer une quantité prédéfinie de la composition aux orteils d'un utilisateur et/ou à des espaces interdigitaux et/ou au pied ou à la main.
PCT/GB2024/052885 2023-11-13 2024-11-13 Composition comprenant de la terbinafine et un polymère destinée à être utilisée dans le traitement de l'onychomycose Pending WO2025104432A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2317378.4A GB202317378D0 (en) 2023-11-13 2023-11-13 Composition and methods of treatment
GB2317378.4 2023-11-13
GB2318443.5 2023-12-01
GBGB2318443.5A GB202318443D0 (en) 2023-12-01 2023-12-01 Compositions and methods of treatment

Publications (1)

Publication Number Publication Date
WO2025104432A1 true WO2025104432A1 (fr) 2025-05-22

Family

ID=93607555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2024/052885 Pending WO2025104432A1 (fr) 2023-11-13 2024-11-13 Composition comprenant de la terbinafine et un polymère destinée à être utilisée dans le traitement de l'onychomycose

Country Status (1)

Country Link
WO (1) WO2025104432A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019002862A1 (fr) 2017-06-30 2019-01-03 Blueberry Therapeutics Limited Nanoparticules formées à partir d'un polymère et de terbinafine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019002862A1 (fr) 2017-06-30 2019-01-03 Blueberry Therapeutics Limited Nanoparticules formées à partir d'un polymère et de terbinafine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUHR RAINARD ET AL: "Results from a Phase 1/2 trial of BB2603, a terbinafine-based topical nano-formulation, in onychomycosis and tinea pedis", MYCOSES, vol. 65, no. 6, 20 May 2022 (2022-05-20), GB, pages 661 - 669, XP093233135, ISSN: 0933-7407, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/myc.13448> DOI: 10.1111/myc.13448 *
LEIGH EMMA: "Blueberry Therapeutics Meets Primary And Secondary Endpoints In Phase 2b Trial In Onychomycosis | Blueberry Therapeutics", 13 November 2023 (2023-11-13), XP093236854, Retrieved from the Internet <URL:https://www.blueberrytherapeutics.com/blueberry-therapeutics-meets-primary-and-secondary-endpoints-in-phase-2b-trial-in-onychomycosis/> *

Similar Documents

Publication Publication Date Title
US12161764B2 (en) Composition and methods of treatment
TWI232756B (en) Nail lacquer composition for drug delivery
JP7320559B2 (ja) 組成物および治療方法
JP2023182607A (ja) 組成物および治療方法
EP1931309B1 (fr) Composition antifongique
WO2025104432A1 (fr) Composition comprenant de la terbinafine et un polymère destinée à être utilisée dans le traitement de l&#39;onychomycose
JP2025000870A (ja) ポリマー及びテルビナフィンから形成されるナノ粒子
US20180104227A1 (en) Nail lacquer composition containing ciclopirox
AU2023289387A1 (en) Topical naftifine compositions
Vora Formulation and Optimization of Transungual Drug Delivery of Antifungal Agent
HK1117403B (en) Antifungal composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24809709

Country of ref document: EP

Kind code of ref document: A1